KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average): 2010-2024

Historic Shares Outstanding (Diluted Average) for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2024 value amounting to $56.0 million.

  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 0.96% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 0.96%. This contributed to the annual value of $56.0 million for FY2024, which is 0.81% up from last year.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $56.0 million in FY2024, which was up 0.81% from $55.5 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $61.7 million during FY2022, and its lowest value of $53.7 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $57.7 million, with its median value being $56.0 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) climbed by 13.47% in 2022, and later fell by 10.01% in 2023.
  • Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $53.7 million in 2020, then rose by 1.24% to $54.4 million in 2021, then rose by 13.47% to $61.7 million in 2022, then decreased by 10.01% to $55.5 million in 2023, then rose by 0.81% to $56.0 million in 2024.